Microbiome-focused company receives $6 million in funding to advance gut health platform technologies. The post 32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics appeared first on 32 Bio Sciences .